“…Sabe-se que podem diferir qualitativa e quantitativamente da referência, demonstram que os estudos de equivalência farmacêutica exigidos atualmente no momento do registro podem não ser suficientes para garantir a eficácia e segurança da cópia. 22…”
“…Sabe-se que podem diferir qualitativa e quantitativamente da referência, demonstram que os estudos de equivalência farmacêutica exigidos atualmente no momento do registro podem não ser suficientes para garantir a eficácia e segurança da cópia. 22…”
Abstract. This note aims to clarify the Brazilian regulatory bioequivalence recommendations for approval of generic topical dermatological drug products, since the legal framework of the "Brazilian Health Surveillance Agency" (ANVISA) is only available in Portuguese. According to Resolutions RE n. 1170 (December 19th 2006 and RDC n. 37 (August 3rd 2011) in Brazil, only in vitro studies are required for registration of generic topical dermatological drug products. Current Regulatory Agenda of ANVISA, which contains possible future resolutions to be revised over 2015-2016, includes a discussion on biowaiver requirements and on possible in vitro and in vivo comparability tests for these products.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.